A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. (July 2014)
- Record Type:
- Journal Article
- Title:
- A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. (July 2014)
- Main Title:
- A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands
- Authors:
- Swinney, David C
Beavis, Paul
Chuang, Kai‐Ting
Zheng, Yue
Lee, Ina
Gee, Peter
Deval, Jerome
Rotstein, David M
Dioszegi, Marianna
Ravendran, Palani
Zhang, Jun
Sankuratri, Surya
Kondru, Rama
Vauquelin, Georges - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12683-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>The human CCR5 receptor is a co‐receptor for HIV‐1 infection and a target for anti‐viral therapy. A greater understanding of the binding kinetics of small molecule allosteric ligand interactions with CCR5 will lead to a better understanding of the binding process and may help discover new molecules that avoid resistance.</p> </sec> <sec id="bph12683-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Using [<sup>3</sup>H] maraviroc as a radioligand, a number of different binding protocols were employed in conjunction with simulations to determine rate constants, kinetic mechanism and mutant kinetic fingerprints for wild‐type and mutant human CCR5 with maraviroc, aplaviroc and vicriviroc.</p> </sec> <sec id="bph12683-sec-0003" sec-type="section"> <title>Key Results</title> <p>Kinetic characterization of maraviroc binding to the wild‐type CCR5 was consistent with a two‐step kinetic mechanism that involved an initial receptor–ligand complex (RA), which transitioned to a more stable complex, R'A, with at least a 13‐fold increase in affinity. The dissociation rate from R'A, <italic>k</italic><sub>−2</sub>, was 1.2 × 10<sup>−3</sup> min<sup>−1</sup>. The maraviroc time‐dependent transition was influenced by F85L, W86A, Y108A, I198A and Y251A mutations of CCR5.</p> </sec> <sec<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12683-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>The human CCR5 receptor is a co‐receptor for HIV‐1 infection and a target for anti‐viral therapy. A greater understanding of the binding kinetics of small molecule allosteric ligand interactions with CCR5 will lead to a better understanding of the binding process and may help discover new molecules that avoid resistance.</p> </sec> <sec id="bph12683-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Using [<sup>3</sup>H] maraviroc as a radioligand, a number of different binding protocols were employed in conjunction with simulations to determine rate constants, kinetic mechanism and mutant kinetic fingerprints for wild‐type and mutant human CCR5 with maraviroc, aplaviroc and vicriviroc.</p> </sec> <sec id="bph12683-sec-0003" sec-type="section"> <title>Key Results</title> <p>Kinetic characterization of maraviroc binding to the wild‐type CCR5 was consistent with a two‐step kinetic mechanism that involved an initial receptor–ligand complex (RA), which transitioned to a more stable complex, R'A, with at least a 13‐fold increase in affinity. The dissociation rate from R'A, <italic>k</italic><sub>−2</sub>, was 1.2 × 10<sup>−3</sup> min<sup>−1</sup>. The maraviroc time‐dependent transition was influenced by F85L, W86A, Y108A, I198A and Y251A mutations of CCR5.</p> </sec> <sec id="bph12683-sec-0004" sec-type="section"> <title>Conclusions and Implications</title> <p>The interaction between maraviroc and CCR5 proceeded according to a multi‐step kinetic mechanism, whereby initial mass action binding and later reorganizations of the initial maraviroc–receptor complex lead to a complex with longer residence time. Site‐directed mutagenesis identified a kinetic fingerprint of residues that affected the binding kinetics, leading to the conclusion that allosteric ligand binding to CCR5 involved the rearrangement of the binding site in a manner specific to each allosteric ligand.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 171:Number 14(2014:Jul.)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 171:Number 14(2014:Jul.)
- Issue Display:
- Volume 171, Issue 14 (2014)
- Year:
- 2014
- Volume:
- 171
- Issue:
- 14
- Issue Sort Value:
- 2014-0171-0014-0000
- Page Start:
- 3364
- Page End:
- 3375
- Publication Date:
- 2014-07
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.12683 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4087.xml